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Background. Access to antiretroviral therapy may have changed condom use behavior. In January 2008,
recommendations on condom use for human immunodeficiency virus (HIV)–positive persons were published in
Switzerland, which allowed for unprotected sex under well-defined circumstances (“Swiss statement”). We studied
the frequency, changes over time, and determinants of unprotected sex among HIV-positive persons.
Methods. Self-reported information on sexual preference, sexual partners, and condom use was collected at
semi-annual visits in all participants of the prospective Swiss HIV Cohort Study from April 2007 through March
2009. Multivariable logistic regression models were fit using generalized estimating equations to investigate as-
sociations between characteristics of cohort participants and condom use.
Findings. A total of 7309 participants contributed to 21,978 visits. A total of 4291 persons (80%) reported
sexual contacts with stable partners, 1646 (30%) with occasional partners, and 557 (10%) with stable and occasional
partners. Of the study participants, 5838 (79.9%) of 7309 were receiving antiretroviral therapy, and of these, 4816
patients (82%) had a suppressed viral load. Condom use varied widely and differed by type of partner (visits with
stable partners, 10,368 [80%] of 12,983; visits with occasional partners, 4300 [88%] of 4880) and by serostatus
of stable partner (visits with HIV-negative partners, 7105 [89%] of 8174; visits with HIV-positive partners, 1453
[48%] of 2999). Participants were more likely to report unprotected sex with stable partners if they were receiving
antiretroviral therapy, if HIV replication was suppressed, and after the publication of the “Swiss statement.”
Noninjection drug use and moderate or severe alcohol use were associated with unprotected sex.
Conclusions. Antiretroviral treatment and plasma HIV RNA titers influence sexual behavior of HIV-positive
persons. Noninjection illicit drug and alcohol use are important risk factors for unprotected sexual contacts.
Epidemiological data indicate that sexual risk behavior
may have increased in recent years among human im-
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munodeficiency virus (HIV)–positive men who have
sex with men (MSM) [1–2], injection drug users (IDUs)
[3], and heterosexual persons [4]. Before potent anti-
retroviral therapy (ART) was available, the most im-
portant prevention measure for transmission of virus
in HIV-positive persons was condom use. There is a
recent debate as to whether condom use is necessary
if HIV replication is suppressed. In January 2008, Swit-
zerland’s National HIV/AIDS Commission published
recommendations on condom use (hereafter, the “Swiss
statement”) stating that HIV-positive persons may dis-
continue condom use in a stable partnership if (1) their
partners agreed, (2) if they were receiving ART, (3) if
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the viral load was suppressed to undetectable levels for at least
6 months, and (4) if other sexually transmitted infections were
absent [5]. Consequently, ART status and plasma viral load
may now influence sexual behavior in a stable partnership.
Alcohol use, injection and noninjection illicit drug use [6],
and sex work [7] are associated with unprotected sexual con-
tacts; sex with occasional partners or concurrency of different
partners are associated with HIV infection and other sexually
transmitted infections [8]. Different approaches to risk reduc-
tion, including serosorting (unprotected sex with occasional or
stable partners who are believed to be seroconcordant) or ne-
gotiated safety (unprotected sex with a seroconcordant main
partner) are of unproven efficacy [9, 10]. Their failure might
explain new HIV infections among MSM.
To individualize HIV prevention, it is crucial to identify risks
for unprotected sex. We studied the frequency of and deter-
minants for unprotected sexual contacts, such as age, influence
of ART, suppressed viral replication, illicit injection or non-
injection drug use, and alcohol consumption on condom use.
We analyzed self-reported condom use separately in MSM, het-
erosexual men, heterosexual women, and current IDUs, and
we distinguished sexual contacts with stable versus occasional
partners. In investigating participants of the Swiss HIV Cohort
Study, we were also able to study the possible impact of the
“Swiss statement” on the local HIV-positive population and
their partners.
PATIENTS AND METHODS
Study design and data collection. Established in 1988, the
Swiss HIV Cohort study (SHCS) is a prospective cohort study
with continued enrolment of HIV-infected persons aged 16
years who attend outpatient clinics of 7 cohort centers, hospitals
affiliated with centers, or private practitioners collaborating
with the centers [11]. Standardized data collection forms con-
taining demographic, psychosocial, clinical, laboratory, and
treatment information are completed every 6 months by phy-
sicians and study nurses.
An interviewer-administered questionnaire on condom use
(always; sometimes; never; no answer) of cohort participants,
type of partners (stable vs occasional), and HIV serostatus (neg-
ative; positive; unknown) of stable partners within the last 6
months was introduced in April 2000. Serostatus of occasional
partners was not elicited, because we did not expect reliable
results. Questions on alcohol consumption were added in Au-
gust 2005, and questions on injection and noninjection drug
use were introduced in April 2007.
Study participants. All participants with at least 1 cohort
visit from 1 April 2007 through 31 March 2009 with complete
information on sexual behavior, drug use, participation in an
opiate substitution program, alcohol intake, ethnicity, CD4+ cell
count, and HIV RNA level within 3 months prior to the cohort
visit were included in the analyses. Cohort inclusion visits were
excluded to avoid newly diagnosed HIV infections and, hence,
to overestimate potentially unprotected sexual contacts within
the preceding month. The protocol of the SHCS was approved
by local ethical commissions, and written informed consent
was obtained from all participants.
Definitions and measures. Initial analyses indicated that it
was necessary to separate unprotected sexual contacts in stable
partnerships from unprotected sexual behavior with occasional
partners. In addition, an effect modification by sex and drug
consumption behavior was observed. Participants were assigned
to the group of MSM if their mode of HIV acquisition was
homosexual sex. If they were infected by heterosexual contacts,
they were assigned to the groups of heterosexual men or
women. Male or female current IDUs and participants in an
opiate substitution program within 3 years prior to the visit
analyzed were categorized to the group of cIDU. Former IDUs
who had completely abstained from IDU for at least 3 years
and were not enrolled in an opiate substitution program and
persons who solely consumed noninjection drugs were analyzed
as heterosexuals or MSM depending on their sexual orientation.
We defined unprotected sexual contacts as reporting that con-
doms were used sometimes or never since the last semi-annual
cohort visit with (1) stable partners whose HIV status was
reported to be negative or unknown or (2) with occasional
partners.
To study the possible impact of the “Swiss statement”, which
issued at the end of January 2008, we divided the observation
period into 2 periods (1 April 2007 through 31 January 2008
and 1 February 2008 through 31 March 2009). Further analyses
were made to differentiate whether there was an increase in
unprotected sexual behavior close to the time of the “Swiss
statement” or whether the increase was progressive during
2007–2009, and we looked at interactions between time periods
and the effect of having a viral load below the level of detection.
ART status was categorized as (1) treatment-naive, (2) re-
ceiving ART with suppressed viral load (!40 copies/mL), and
(3) receiving ART with detectable viral load (140 copies/mL in
different consecutive visits). Alcohol use was stratified accord-
ing to the World Health Organization definition of severe (fe-
male subjects, 140 g/day; male subjects, 160 g/day), moderate
(female subjects, 20–40 g/day; male subjects, 40–60 g/day), and
light use (female subjects, !20 g/day; male subjects, !40 g/day).
The term “cocktail” was used if participants consumed 11 non-
injection drug. The term “any illicit drug” describes any in-
jection or noninjection drug use.
Statistical analysis. Categorical variables were compared
with use of the x2 test, and continuous variables were assessed
with nonparametric methods (ie, Wilcoxon rank-sum test).
Univariable and multivariable logistic regression models were
fit using generalized estimating equations to determine the as-
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Figure 1. Patient flowchart. cIDU, current drug users or persons in an opiate substitution programme; HIV, human immunodeficiency virus; MSM,
men who have sex with men.
sociations between unprotected sexual intercourse, age (per 10
years), calendar period before and after publication of the
“Swiss statement”, ART use, alcohol consumption, and illicit
drug use. The combined variable “any illicit drug use” could
be analyzed in each of the 4 groups, but numbers for individual
drugs, recently acquired syphilis, and ethnicity were too small
in some groups, resulting in model instability of multivariable
analyses.
Participants could contribute with different visits with po-
tentially changed reported sexual behavior, illicit drug use, and
ART status. Estimates of the associations between the outcome
and variables are presented with odds ratios (ORs) and 95%
confidence intervals (CIs).
We performed sensitivity analyses evaluating predictors of
inconsistent condom use in stable partnerships once irrespec-
tive of the serostatus of the partner and once in seroconcordant
couples. We used Stata software, version 11.0 (StataCorp), for
analyses.
RESULTS
Selection and characteristics of cohort participants. The in-
clusion of SHCS participants is shown in Figure 1. From 1
April 2007 through 31 March 2009, a total of 7928 persons
were observed. Of these, 619 were excluded because of incom-
plete information. Excluded individuals were more likely to be
MSM (9% vs 7%), younger (median age, 39 vs 43 years), of
nonwhite ethnicity (7% vs 12%), ART-naive (19% vs 11%),
have recently acquired syphilis (19% vs 8%), have consumed
illicit drugs (13% vs 7%), or to be severe alcohol drinkers (11%
vs 7%) ( for all). The 7309 selected participants con-P ! .05
tributed to 28,375 person-years of follow-up and 21,978 visits.
Characteristics of participants are summarized according to
stratified groups in Table 1. The median age of all participants
in the 4 groups was 43 years (interquartile range, 38–49 years).
Nineteen percent (1355 of 7309 patients) were of nonwhite
ethnicity, and among those patients, 838 (43%) were women.
A total of 5838 (79.9%) of the participants were receiving ART,
and 82% of these patients had an undetectable viral load at the
time of cohort visits. Among all participants, 63% reported
alcohol consumption categorized as light, 5% reported mod-
erate consumption, and 2% reported severe consumption. Con-
sumption of illicit drugs was reported by 7% of MSM, by 3%
of heterosexual men, and by 1% of heterosexual women.
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Table 1. Baseline Characteristics of 7309 Human Immunodeficiency Virus (HIV)–Seropositive Cohort Participants
Variable
No. (%) of participants
MSM
(n p 2840)
Heterosexual
men
(n p 1650)
Heterosexual
women
(n p 1934)
cIDU
(n p 885)
All
(n p 7309)
Age
16–29 Years 140 (5) 78 (5) 201 (10) 31 (4) 450 (6)
30–39 Years 666 (23) 306 (18) 648 (34) 224 (25) 1844 (25)
40–49 Years 1211 (43) 711 (43) 771 (40) 515 (58) 3208 (44)
50–59 Years 542 (19) 442 (21) 202 (10) 110 (12) 1196 (17)
60 Years 281 (10) 213 (13) 112 (6) 5 (1) 611 (8)
Nonwhite ethnicity 188 (7) 301 (18) 838 (43) 28 (3) 1355 (19)
Receiving ART
HIV RNA level 40 copies/mL 378 (13) 242 (15) 252 (13) 150 (17) 1022 (14)
HIV RNA level !40 copies/mL 1825 (64) 1153 (70) 1286 (67) 552 (62) 4816 (66)
Alcohol use
Light 1621 (57) 757 (46) 1803 (93) 435 (49) 4616 (63)
Moderate 89 (3) 90 (5) 107 (6) 71 (8) 357 (5)
Severe 39 (1) 31 (2) 23 (1) 61 (7) 11 (0)
New syphilis in study period 64 (2) 9 (0) 1 (0) 2 (0) 76 (1)
Opiate substitution 0 (0) 0 (0) 0 (0) 673 (76) 673 (9)
Any illicit drug use 211 (7) 42 (3) 17 (1) 349 (39) 619 (8)
Heroin use
Noninjection 2 (0) 2 (0) 2 (0) 75 (8) 81 (1)
Injection 0 (0) 0 (0) 0 (0) 124 (14) 124 (2)
Cocaine use
Noninjection 129 (5) 34 (2) 12 (1) 68 (8) 243 (3)
Injection 0 (0) 0 (0) 0 (0) 171 (19) 171 (2)
Cannabis use 341 (12) 228 (14) 119 (6) 342 (39) 1030 (14)
Use of poppers (alkyl nitrites) 28 (1) 0 (0) 0 (0) 0 (0) 28 (0)
Amphetamine use 78 (3) 9 (1) 0 (0) 7 (1) 99 (1)
Benzodiazepine use 0 (0) 0 (0) 0 (0) 37 (4) 39 (1)
g-Hydroxybutyric acid use 20 (1) 0 (0) 0 (0) 3 (0) 23 (0)
Use of drug cocktail (multiple noninjection drugs) 27 (1) 1 (0) 0 (0) 2 (0) 30 (0)
NOTE. ART, antiretroviral therapy; cIDU, current injection drug user or persons in an opiate substitution program within 3 years of the visit
analyzed; HIV, human immunodeficiency virus; MSM, men who have sex with men.
Among the cIDU group, 76% were in an opiate substitution
program, and 39% reported use of any illicit drug.
Condom use. Figure 2 depicts data for MSM, heterosexual
men, heterosexual women, and cIDUs regarding type of part-
ners, HIV serostatus of partners, proportion of reported con-
dom use, and proportion of participants with suppressed HIV
RNA at the time of the cohort visit. Sexual contacts exclusively
with stable partners were reported by MSM, heterosexual men,
heterosexual women, and cIDUs in 46.1%, 79.8%, 91.2%, and
75.1% of cohort visits, respectively. Sexual contacts with both
stable and occasional partners were reported by the different
groups in 17.7%, 3.6%, 1.0%, and 3.4% of the visits, respec-
tively, and sexual contacts with only occasional partners were
reported in 36.2%, 16.9%, 7.8%, and 21.5% of the visits, re-
spectively.
In all 4 groups of cohort participants, the rate of consistent
condom use was lower with occasional partners than with stable
partners (88% vs 92%; ). The proportion of self-re-P ! .001
ported consistent condom use was 89% among participants
with HIV-negative stable partners, 48% among those with HIV-
positive stable partners, and 80% among those with occasional
partners. Participants with only occasional partners reported
consistent condom use in 87% (MSM), 93% (heterosexual
men), 91% (heterosexual women), and 80% (cIDUs) of visits.
The proportion of visits at which participants had undetectable
viral load is also shown in Figure 2.
Determinants of unprotected sexual contacts. Figure 3
shows results of univariable and adjusted multivariable analyses
of risks for unprotected sexual contacts in the different groups
of cohort participants, separated for participants with stable
versus occasional partners. Unprotected sexual contacts were
more likely to be associated with the following characteristics:
• Time period after the publication of the “Swiss statement”
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Figure 2. Results of 16,155 of 21,978 follow-up visits with information on type of sexual partners, human immunodeficiency virus (HIV) serostatus
of sexual partners, reported condom use of Swiss HIV Cohort Study participants, and proportion of cohort participants with plasma HIV RNA below
the level of detection, stratified into 4 groups. A, men who have sex with man. B, heterosexual men. C, heterosexual women. D, current intravenous
drug users or persons in an opiate substitution programme. HIV bld, proportion of visits with HIV RNA below the level of detection, in relation to
the respective reported condom use.
on condom use: all participant groups with stable partners,
including MSM (OR, 1.88; 95% CI, 1.39–2.55), heterosexual
men (OR, 1.53; 95% CI, 1.26–1.85), heterosexual women
(OR, 2.04; 95% CI, 1.69–2.45), cIDUs (OR, 1.67; 95% CI,
1.17–2.38); and MSM with occasional partners (OR, 1.24;
95% CI, 1.03–1.48).
• Suppressed viral replication: MSM (OR, 2.41; 95% CI, 1.35–
4.30) and heterosexual women with stable partners (OR, 2.73;
95% CI, 1.87–3.99).
• Younger MSM, irrespective of occasional (OR per 10 years
older, 0.86; 95% CI, 0.75–0.99) or stable partnership (OR,
0.72; 95% CI, 0.59–0.87); younger heterosexual men (OR,
0.76; 95% CI, 0.65–0.91); women (OR, 0.77; 95% CI, 0.66–
0.89), and cIDUs with stable partners (OR, 0.64; 95% CI,
0.41–0.97).
• Moderate or severe alcohol use: in heterosexual women (OR,
1.51; 95% CI, 1.05–2.17) and in cIDUs with stable partners
(OR, 2.40; 95% CI, 1.48–3.87), and in heterosexual men with
occasional partners (OR, 2.31; 95% CI, 1.12–4.77).
• Any illicit drug use: MSM (OR, 1.71; 95% CI, 1.05–2.78)
and heterosexual women with stable partners (OR, 2.78; 95%
CI, 1.16–6.68); and among groups with occasional partners,
including MSM (OR, 2.85; 95% CI, 1.04–7.78), heterosexual
men (OR, 2.94; 95% CI, 1.07–8.08), and heterosexual women
(OR, 7.67; 95% CI, 2.13–27.57).
Associations between different illicit drugs and unprotected
sexual contacts. In addition to the results of alcohol and drug
use, as described in Figure 3, having unprotected sexual contacts
was significantly associated with the following illicit drugs:
• Nasal cocaine in MSM with stable (OR, 2.72; 95% CI, 1.42–
HIV/AIDS • CID 2010:51 (1 December) • 1319
Figure 3. Results of univariable and multivariable analyses of risks for unprotected sex with stable partners (12,983 follow-up visits) (A) and with
occasional partners (4889 follow-up visits) (B). Multivariable models were adjusted for all variables listed. ART, antiretroviral therapy; CI, confidence
interval; IDU, injection drug use; MSM, men who have sex with men; VL bld, plasma HIV RNA load below the level of detection.
5.18) and with occasional partners (OR, 2.55; 95% CI, 1.76–
3.70).
• Cannabis (OR, 1.45; 95% CI, 1.07–1.98; ), poppersPp .071
(OR, 2.13; 95% CI, 1.29–3.52), methamphetamine (OR, 2.37;
95% CI, 1.58–3.60), g-hydroxybutyric acid (OR, 2.44; 95%
CI, 1.11–5.36), and drug cocktails (OR, 2.49; 95% CI, 1.24–
5.00) in MSM with occasional partners.
• Cannabis (OR, 1.51; 95% CI, 1.09–2.08) among heterosexual
men with stable partners.
Interactions between time periods and having a viral load
below the level of detection. In all participant groups with
stable partners, a progressive increase in unprotected sex could
be observed over time, and interestingly, in MSM and hetero-
sexual females, there was already a trend toward unprotected
sex before January 2008 (Table 2).
The influence of the “Swiss statement” was markedly in-
creased among MSM, heterosexual males, and heterosexual fe-
males with a stable partner receiving ART and a suppressed
viral load (MSM: OR, 2.81 [95% CI, 1.37–5.80]; heterosexual
males: OR, 1.58 [95% CI, 1.00–2.48]; heterosexual females: OR,
2.14 [95% CI, 1.43–3.22]). In cIDUs, only a trend was found
(OR, 1.65; 95% CI, 0.92–2.99).
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Table 2. Odds Ratios for Unprotected Sex in Stable Partnerships
in Relation to the Publication of the “Swiss Statement” in Dif-
ferent Participant Groups
Group, period
Odds ratio
(95% CI) P a
MSM !.001
April 2007–August 2007 0.56 (0.35–0.92)
September 2007–January 2008 0.81 (0.54–1.22)
February 2008–June 2008b 1
July 2008–October 2008 1.30 (0.93–1.82)
November 2008–March 2009 1.63 (1.16–2.29)
Heterosexual men !.001
April 2007–August 2007 0.75 (0.59–0.96)
September 2007–January 2008 0.83 (0.65–1.10)
February 2008–June 2008b 1
July 2008–October 2008 1.32 (1.05–1.66)
November 2008–March 2009 1.21 (0.96–1.52)
Heterosexual women !.001
April 2007–August 2007 0.58 (0.45–0.75)
September 2007–January 2008 0.60 (0.47–0.77)
February 2008–June 2008b 1
July 2008–October 2008 1.22 (1.00–1.51)
November 2008–March 2009 1.34 (1.11–1.63)
cIDU .084
April 2007–August 2007 0.66 (0.42–1.03)
September 2007–January 2008 0.63 (0.41–0.97)
February 2008–June 2008b 1
July 2008–October 2008 1.01 (0.70–1.46)
November 2008–March 2009 1.13 (0.75–1.68)
NOTE. CI, confidence intervals; cIDU, current drug users or persons in an
opiate substitution program; MSM, men who have sex with men.
a Test for trend.
b Reference period: publication of the “Swiss statement.”
Sensitivity analyses. In concordant partnerships, having an
HIV-positive stable partner was strongly associated with un-
protected sex among all groups of cohort participants: the OR
was 15.55 (95% CI, 12.36–19.56) for MSM, 6.77 (95% CI, 5.14–
8.93) for heterosexual males, 6.88 (95% CI, 5.38–8.80) for het-
erosexual females, and 7.68 (95% CI, 4.98–11.84) for cIDUs.
Analyzing inconsistent condom use in stable partnerships ir-
respective of the serostatus of the partner showed comparable
results (Figure 3).
DISCUSSION
We found a substantial variation in condom use among HIV-
positive participants in our large prospective observational co-
hort. The proportion of consistent condom use was 89% among
participants with HIV-seronegative stable partners, 48% with
HIV-seropositive stable partners, and 88% with occasional part-
ners.
Whether ART may promote unprotected sexual intercourse
has previously been discussed [12, 13]. In contrast to earlier
results from our cohort, which did not find an association
between viral load and sexual behavior [14, 15], we now ob-
served an association of a suppressive ART and unprotected
sexual contacts in MSM and heterosexual women with stable
partners, indicating that some groups with HIV infection have
adopted the belief that treatment of HIV infection is a sufficient
HIV-prevention measure [16]. Precise estimates of the risk from
unprotected intercourse when the infected person is receiving
successful HIV treatment are not available [17, 18]. SHCS par-
ticipants receiving successful ART who were observed in the
year 2007 still had suppressed viral load in 91.9% at the next
semi-annual follow-up visit, but 2.2% had discontinued treat-
ment, and 5.9% had a viral rebound [19]. A model-based anal-
ysis calculated a cumulative probability of transmission to the
serodifferent partner of 0.0022 per year [20]. Authors claimed
a substantial increase in HIV infection incidence if the non-
infectiousness of effectively treated patients was widely ac-
cepted, and hence, condom use decreased. However, there is
increasing evidence that viral-suppressive ART reduces sexual
infectiousness of HIV, and the World Health Organization
thinks of expanding ART coverage to all people with a diagnosis
of HIV infection in the purpose of HIV infection prevention
[21].
We observed that the probability of reporting unprotected
sexual contacts was increasing over time among cohort partic-
ipants with stable partners, as well as among MSM with oc-
casional partners. The effect of the “Swiss statement” was most
pronounced in groups with stable partners who had an un-
detectable viral load, indicating that the Swiss population is
able to accept such complex recommendations. Of note, the
change of policy led, not to an increase in observed new HIV
infections in Switzerland [22]. The association of unprotected
sex and the “Swiss statement” either results from a change in
the social acceptability of having sex without condoms after
the publication of the “Swiss statement”, or the result may
indicate a real change in sexual behavior. Our results show that
there was already a trend toward unprotected sex before January
2008. Other studies have assessed time trends in the sexual
practices of HIV-positive persons, but most of them did not
find an increase in unprotected sexual intercourse over time
[3, 14, 15, 23].
Cohort participants having relations with concordant part-
ners were more likely to report unprotected sexual contact [1].
Whether condom use is needed if both partners are HIV se-
ropositive is controversial. Although rare cases of HIV super-
infections have been described in persons with long-term HIV
infection who are receiving ART, the risk of unprotected sexual
contacts in individuals with a suppressed HIV RNA level seems
low. However, unprotected sexual contacts are associated with
transmission of other sexually transmitted diseases, which con-
secutively may lead to a transient increase in viral load in the
genital compartment and temporarily may not only increase
HIV transmission but also the risk for HIV superinfection [24].
HIV/AIDS • CID 2010:51 (1 December) • 1321
As in other studies [14, 15, 23, 25], participants of older age,
especially those in a stable partnership, were less likely to report
unprotected sex. Similar to the Vespa Study [26, 27], we found
that illicit noninjection drug consumption and alcohol use in-
creased the risk for unprotected sexual contacts among MSM,
heterosexual man, and heterosexual women with occasional
partners. Alcohol use was associated with unprotected sexual
contacts among cIDUs with stable partners, indicating the
added danger when both substance dependence and alcohol
use are present.
Possible limitations of our study are the uncertain accuracy
of self-reported information on sexual behavior, illicit drug use,
and alcohol consumption assessed by face-to-face interviews.
A more anonymous mode of assessment (eg, computer-assisted
interviewing or self-administered questionnaires) might have
led to higher reporting of nonnormative and risky behavior.
Underreporting of socially unacceptable sexual behavior or, in
contrast, more-accurate reporting because of perceived changes
in social acceptance of unprotected sexual contacts after pub-
lication of the “Swiss statement” may have influenced the an-
swers of participants. The relation of patient and provider, their
degree of confidence and trust, or the providers’ values, none
of which were measured, may also have influenced our results.
Furthermore, some participants with obvious high-risk behav-
ior (eg, recently acquired syphilis) have refused to disclose de-
tails on sexual practices and thus were excluded from analyses.
Another bias may have resulted from individuals with lifestyles
associated with more-frequent unprotected sex and nonparti-
cipation in the SHCS (eg, drug-addicted sex workers). Strengths
of our study include its statistical power, because of the cohort’s
size, and the prospective design, which allows analyses of time
trends of unprotected sexual behavior and of changes in relation
to the publication date of the “Swiss statement”. In contrast
to others [23], we precluded a bias in reporting of unprotected
sexual contacts by acutely HIV-infected persons by deleting
cohort inclusion visits for analyses. We believe that our results
are highly representative, because 93.4% of the cohort partic-
ipants responded to questions on sexual behavior.
In conclusion, condom use by HIV-seropositive persons var-
ies widely. Individualized counselling to prevent sexual HIV
transmission is part of patient care. More focus should be
placed on patterns of alcohol and illicit drug use, which may
not only improve adherence to ART but also prevent HIV
transmission. Among persons with concurrent partners, coun-
selling is needed to address other sexually transmitted infections
[28], including hepatitis C virus infection [29], and the risk of
increased sexual transmission of HIV in case of co-infections.
Because ART influences sexual behavior in HIV serodifferent
partners, adherence to treatment and plasma viral load should
be regularly monitored in the HIV-positive partner, and coun-
selling of couples should be advocated.
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